NFKB1 and neoplasm: Bortezomib, a proteasome inhibitor, exerted anti-tumor activity in MM and MCL cells by stabilization of IκBα in the NF-κB signaling pathway; however, bortezomib alone proved to be insufficient for effective treatment.